O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	trial
O	26	28	of
O	29	35	weekly
O	36	38	vs
O	38	39	.
O	40	45	every
O	46	47	2
O	48	53	weeks
O	54	56	vs
O	56	57	.
O	58	63	every
O	64	65	3
O	66	71	weeks
B-intervention	72	84	nanoparticle
I-intervention	85	92	albumin
I-intervention	92	93	-
I-intervention	93	98	bound
I-intervention	99	109	paclitaxel
I-intervention	110	114	with
I-intervention	115	126	bevacizumab
O	127	129	as
O	130	135	first
O	135	136	-
O	136	140	line
O	141	153	chemotherapy
O	154	157	for
O	158	168	metastatic
O	169	175	breast
O	176	182	cancer
O	182	183	.

O	184	196	Nanoparticle
O	197	204	albumin
O	204	205	-
O	205	210	bound
O	211	221	paclitaxel
O	222	223	(
O	223	226	nab
O	226	227	-
O	227	228	P
O	228	229	)
O	230	233	and
O	234	245	bevacizumab
O	246	250	have
O	251	255	each
O	256	268	demonstrated
O	269	277	efficacy
O	278	280	in
O	281	289	patients
O	290	294	with
O	295	298	MBC
O	298	299	.

O	300	304	This
O	305	310	trial
O	311	314	was
O	315	323	designed
O	324	326	to
O	327	334	further
O	335	342	develop
O	343	346	nab
O	346	347	-
O	347	348	P
O	349	351	by
O	352	362	evaluating
O	363	366	its
O	367	375	efficacy
O	376	379	and
O	380	386	safety
O	387	392	using
O	393	398	every
O	399	400	3
O	401	406	weeks
O	407	408	(
O	408	411	q3w
O	411	412	)
O	412	413	,
O	414	419	every
O	420	421	2
O	422	427	weeks
O	428	429	(
O	429	432	q2w
O	432	433	)
O	433	434	,
O	435	437	or
O	438	444	weekly
O	445	455	scheduling
O	456	458	in
O	459	470	combination
O	471	475	with
O	476	487	bevacizumab
O	488	490	as
O	491	496	first
O	496	497	-
O	497	501	line
O	502	511	treatment
O	512	514	of
O	515	518	MBC
O	518	519	.

O	520	524	This
O	525	529	open
O	529	530	-
O	530	535	label
O	536	541	phase
O	542	544	II
O	545	550	study
O	551	561	randomized
O	562	570	patients
O	571	573	to
O	574	577	nab
O	577	578	-
O	578	579	P
O	580	583	260
O	584	586	mg
O	586	587	/
O	587	588	m
O	588	589	(
O	589	590	2
O	590	591	)
O	592	595	q3w
O	596	597	(
O	597	600	arm
O	601	602	A
O	602	603	)
O	604	606	vs
O	606	607	.
O	608	611	260
O	612	614	mg
O	614	615	/
O	615	616	m
O	616	617	(
O	617	618	2
O	618	619	)
O	620	623	q2w
O	624	628	with
O	629	639	filgrastim
O	640	641	(
O	641	644	arm
O	645	646	B
O	646	647	)
O	648	650	vs
O	650	651	.
B-control	652	655	130
I-control	656	658	mg
I-control	658	659	/
I-control	659	660	m
I-control	660	661	(
I-control	661	662	2
I-control	662	663	)
I-control	664	670	weekly
I-control	671	684	uninterrupted
O	684	685	,
O	686	689	all
O	690	694	with
O	695	706	bevacizumab
O	707	708	(
O	708	710	15
O	711	713	mg
O	713	714	/
O	714	716	kg
O	717	720	q3w
O	721	724	arm
O	725	726	A
O	726	727	,
O	728	730	10
O	731	733	mg
O	733	734	/
O	734	736	kg
O	737	740	q2w
O	741	745	arms
O	746	747	B
O	748	751	and
O	752	753	C
O	753	754	)
O	754	755	.

O	756	759	The
O	760	767	primary
O	768	777	endpoints
O	778	782	were
B-outcome-Measure	783	790	overall
I-outcome-Measure	791	799	response
I-outcome-Measure	800	804	rate
I-outcome-Measure	805	806	(
I-outcome-Measure	806	809	ORR
I-outcome-Measure	809	810	)
O	811	814	and
B-outcome-Measure	815	823	toxicity
O	823	824	.

B-outcome-Measure	825	829	Time
I-outcome-Measure	830	832	to
I-outcome-Measure	833	838	tumor
I-outcome-Measure	839	850	progression
I-outcome-Measure	851	852	(
I-outcome-Measure	852	855	TTP
I-outcome-Measure	855	856	)
O	857	860	and
B-outcome-Measure	861	868	overall
I-outcome-Measure	869	877	survival
O	878	882	were
O	883	892	secondary
O	893	902	endpoints
O	902	903	.

O	904	906	Of
B-total-participants	907	910	212
O	911	919	patients
O	920	930	randomized
O	930	931	,
B-total-participants	932	935	208
O	936	937	(
O	937	940	arm
O	941	942	A
O	942	943	,
B-intervention-participants	944	946	75
O	946	947	;
O	948	951	arm
O	952	953	B
O	953	954	,
B-intervention-participants	955	957	54
O	957	958	;
O	959	962	arm
O	963	964	C
O	964	965	,
B-control-participants	966	968	79
O	968	969	)
O	970	974	were
O	975	982	treated
O	982	983	.

O	984	987	Arm
O	988	989	B
O	990	993	was
O	994	1000	closed
O	1001	1006	early
O	1007	1010	due
O	1011	1013	to
O	1014	1022	toxicity
O	1022	1023	,
O	1024	1028	with
O	1029	1033	more
B-outcome	1034	1039	grade
I-outcome	1040	1041	≥
I-outcome	1042	1043	2
I-outcome	1044	1051	fatigue
O	1052	1053	(
O	1053	1056	arm
O	1057	1058	A
O	1058	1059	,
B-iv-bin-percent	1060	1062	46
I-iv-bin-percent	1062	1063	%
O	1063	1064	;
O	1065	1068	arm
O	1069	1070	B
O	1070	1071	,
B-iv-bin-percent	1072	1074	62
I-iv-bin-percent	1074	1075	%
O	1075	1076	;
O	1077	1080	arm
O	1081	1082	C
O	1082	1083	,
B-cv-bin-percent	1084	1086	62
I-cv-bin-percent	1086	1087	%
O	1087	1088	)
O	1089	1092	and
B-outcome	1093	1097	bone
I-outcome	1098	1102	pain
O	1103	1104	(
O	1104	1107	arm
O	1108	1109	A
O	1109	1110	,
B-iv-bin-percent	1111	1113	11
I-iv-bin-percent	1113	1114	%
O	1114	1115	;
O	1116	1119	arm
O	1120	1121	B
O	1121	1122	,
B-iv-bin-percent	1123	1125	23
I-iv-bin-percent	1125	1126	%
O	1126	1127	;
O	1128	1131	arm
O	1132	1133	C
O	1133	1134	,
B-cv-bin-percent	1135	1136	5
I-cv-bin-percent	1136	1137	%
O	1137	1138	)
O	1138	1139	.

B-outcome	1140	1153	Neurotoxicity
I-outcome	1154	1159	grade
I-outcome	1160	1161	≥
I-outcome	1162	1163	2
O	1164	1167	was
O	1168	1178	equivalent
O	1179	1185	across
O	1186	1189	the
O	1190	1194	arms
O	1195	1196	(
O	1196	1197	>
O	1198	1200	50
O	1200	1201	%
O	1201	1202	)
O	1203	1206	and
O	1207	1217	reversible
O	1218	1221	for
O	1222	1226	most
O	1227	1235	patients
O	1235	1236	.

B-outcome	1237	1244	Febrile
I-outcome	1245	1256	neutropenia
O	1257	1265	occurred
O	1266	1268	in
O	1269	1270	≤
O	1271	1272	3
O	1272	1273	%
O	1274	1276	of
O	1277	1285	patients
O	1286	1288	in
O	1289	1292	all
O	1293	1297	arms
O	1297	1298	.

B-outcome	1299	1302	ORR
O	1303	1306	was
O	1307	1314	similar
O	1315	1320	among
O	1321	1324	the
O	1325	1329	arms
O	1330	1331	(
O	1331	1334	arm
O	1335	1336	A
O	1336	1337	,
B-iv-bin-percent	1338	1340	45
I-iv-bin-percent	1340	1341	%
O	1341	1342	;
O	1343	1346	arm
O	1347	1348	B
O	1348	1349	,
B-iv-bin-percent	1350	1352	41
I-iv-bin-percent	1352	1353	%
O	1353	1354	;
O	1355	1358	arm
O	1359	1360	C
O	1360	1361	,
B-cv-bin-percent	1362	1364	46
I-cv-bin-percent	1364	1365	%
O	1365	1366	)
O	1366	1367	.

B-outcome	1368	1374	Median
I-outcome	1375	1378	TTP
O	1379	1382	was
O	1383	1391	slightly
O	1392	1398	longer
O	1399	1401	in
O	1402	1405	arm
O	1406	1407	C
O	1408	1409	(
B-iv-cont-median	1409	1410	9
I-iv-cont-median	1410	1411	.
I-iv-cont-median	1411	1412	0
I-iv-cont-median	1413	1419	months
O	1419	1420	)
O	1421	1423	vs
O	1423	1424	.
O	1425	1429	arms
O	1430	1431	A
O	1432	1433	(
B-iv-cont-median	1433	1434	8
I-iv-cont-median	1434	1435	.
I-iv-cont-median	1435	1436	0
I-iv-cont-median	1437	1443	months
O	1443	1444	)
O	1445	1448	and
O	1449	1450	B
O	1451	1452	(
B-cv-cont-median	1452	1453	5
I-cv-cont-median	1453	1454	.
I-cv-cont-median	1454	1455	8
I-cv-cont-median	1456	1462	months
O	1462	1463	)
O	1464	1465	(
O	1465	1472	overall
O	1472	1473	,
O	1474	1475	P
O	1476	1477	=
O	1478	1479	.
O	1479	1482	105
O	1482	1483	)
O	1483	1484	.

O	1485	1496	Significant
B-outcome	1497	1506	antitumor
I-outcome	1507	1515	activity
O	1516	1519	was
O	1520	1528	observed
O	1529	1531	in
O	1532	1535	all
O	1536	1539	the
O	1540	1544	arms
O	1544	1545	.

O	1546	1552	Weekly
O	1553	1556	nab
O	1556	1557	-
O	1557	1558	P
O	1559	1563	with
O	1564	1575	bevacizumab
O	1576	1584	appeared
O	1585	1587	to
O	1588	1592	have
O	1593	1596	the
O	1597	1604	highest
O	1605	1616	therapeutic
O	1617	1622	index
O	1622	1623	.

O	1624	1631	However
O	1631	1632	,
O	1633	1640	sensory
O	1641	1651	neuropathy
O	1652	1655	was
O	1656	1665	treatment
O	1666	1674	limiting
O	1674	1675	,
O	1676	1681	which
O	1682	1690	suggests
O	1691	1695	that
O	1696	1697	a
O	1698	1699	3
O	1700	1705	weeks
O	1706	1708	on
O	1709	1712	and
O	1713	1714	1
O	1715	1719	week
O	1720	1723	off
O	1724	1732	schedule
O	1733	1739	should
O	1740	1742	be
O	1743	1751	explored
O	1751	1752	.
